ZFPM2-AS1 is an oncogene and independent prognostic predictor of poor survival in NSCLCs, and its expression had a positive correlation with tumor size and lymph node metastasis in our clinical data. This evidence concerns the gene ZFPM2 and metastatic malignant neoplasm in the lymph nodes.